826
Participants
Start Date
July 31, 2011
Primary Completion Date
May 31, 2013
Study Completion Date
June 30, 2013
OPC-34712 + ADT
Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Placebo + ADT
Placebo + FDA Approved Antidepressant (ADT)
Placebo + ADT
Placebo + FDA Approved Antidepressant (ADT)
Research Site, Arcadia
Research Site, Beverly Hills
Research Site, Fresno
Research Site, Oceanside
Research Site, San Diego
Research Site, San Francisco
Research Site, Sherman Oaks
Research Site, Denver
Research Site, Norwalk
Research Site, Coral Springs
Research Site, Fort Myers
Research Site, Hialeah
Research Site, Jacksonville
Research Site, Melbourne
Research Site, Orlando
Research Site, Indianapolis
Research Site, Prairie Village
Research Site, Wichita
Research Site, New Orleans
Research Site, Shreveport
Research Site, Belmont
Research Site, Boston
Research Site, Lincoln
Research Site, New York
Research Site, Rochester
Research Site, Dayton
Research Site, Toledo
Research Site, Salem
Research Site, Allentown
Research Site, Bala-Cynwyd
Research Site, Bridgeville
Research Site, Philadelphia
Research Site, San Antonio
Research Site, Murray
Research Site, Woodstock
Research Site, Richmond
Research Site, Seattle
Research Site, Penticton
Research Site, Toronto
Research Site, Gatineau
Research Site, Arcachon
Research Site, Élancourt
Research Site, Orvault
Research Site, Palaiseau
Research Site, Toulouse
Research Site, Bełchatów
Research Site, Katowice
Research Site, Poznan
Research Site, Gdynia
Research Site, Kielce
Research Site, Lublin
Research Site, Tuszyn
Research Site, Warsaw
Research Site, Kosice-Barca
Research Site, Bratislava
Research Site, Levice
Research Site, Michalovce
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY